<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852071</url>
  </required_header>
  <id_info>
    <org_study_id>EFS-ADA</org_study_id>
    <secondary_id>U01AI100801</secondary_id>
    <secondary_id>2P01HL073104</secondary_id>
    <secondary_id>0910-1006</secondary_id>
    <nct_id>NCT01852071</nct_id>
  </id_info>
  <brief_title>Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene</brief_title>
  <official_title>Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orchard Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orchard Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the safety and efficacy of autologous transplantation of&#xD;
      hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID&#xD;
      infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The&#xD;
      level of gene transfer in blood cells and immune function will be measured as endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who&#xD;
      did not have a medically eligible, human leukocyte antigen (HLA)-identical sibling donor for&#xD;
      bone marrow transplantation. The EFS-ADA lentiviral vector with the human ADA cDNA will be&#xD;
      used to transduce autologous CD34+ cells from the bone marrow of these subjects. The subjects&#xD;
      will receive 4 mg/kg busulfan prior to re-infusion of their gene-modified cells. Safety is&#xD;
      the primary endpoint. During the follow-up phase, the investigators aim to determine whether&#xD;
      the cells could engraft and produce mature cells that contain and express the corrected ADA&#xD;
      gene in the absence of pegademase bovine (PEG-ADA) enzyme replacement therapy (ERT), which&#xD;
      will be withheld at Day +30 following transplant. Efficacy studies to evaluate the level of&#xD;
      immune reconstitution, will be performed in the first and second years of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2013</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival is defined as the percentage of subjects alive at 12 months post- treatment with OTL-101 or HSCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival (EvFS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year)</measure>
    <time_frame>12 months</time_frame>
    <description>Event-free survival is defined as the percentage of subjects alive with no &quot;event&quot;, an &quot;event&quot; being the resumption of PEG-ADA ERT or the need for a rescue allogeneic Hematopoietic Stem Cell Transplant (HSCT), or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years)</measure>
    <time_frame>24 months</time_frame>
    <description>OS is defined as the percentage of subjects alive at 24 months post- treatment with OTL-101 or HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EvFS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years)</measure>
    <time_frame>24 months</time_frame>
    <description>Event-free survival is defined as the percentage of subjects alive with no &quot;event&quot;, an &quot;event&quot; being the resumption of PEG-ADA ERT or the need for a rescue allogenic Hematopoietic Stem Cell Transplant (HSCT), or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector Copy Number (VCN) in Peripheral Blood (PB) Granulocytes.</measure>
    <time_frame>24 months</time_frame>
    <description>Vector copy number in the PB granulocyte fraction that was T cell depleted, is a surrogate for amount of engrafted genetically modified Hematopoietic stem cell (HSC) that are producing granulocytes every 3-5 days. VCN analysis was performed by Droplet Digital PCR (ddPCR) on DNA extracted from peripheral blood granulocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VCN in Peripheral Blood Mononuclear Cells (PBMCs)</measure>
    <time_frame>24 months</time_frame>
    <description>PBMC VCN is a measure of the accumulation of peripheral blood leukocytes arising from engrafted, genetically modified HSC. VCN analysis was performed by ddPCR on DNA extracted from PBMC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA Activity in Erythrocytes</measure>
    <time_frame>24 months</time_frame>
    <description>ADA enzyme activity measured to assess the amount of functional gene product produced from the normal ADA transgene delivered by EFS-ADA LV; persistence of ADA enzyme activity over time demonstrates successful engraftment and differentiation of genetically modified HSC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Deoxyadenosine Nucleotide (dAXP) in Erythrocytes</measure>
    <time_frame>24 months</time_frame>
    <description>Decreased dAXP levels coincide with increased ADA enzyme activity, detoxification was used to demonstrate functional ADA enzyme production from the introduced ADA transgene. The threshold for detoxification was &lt;100 Î¼mol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD3+ T Cell Counts (2 Years)</measure>
    <time_frame>24 months</time_frame>
    <description>Immune reconstitution was assessed by change in CD3+ T Cell counts over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Single Integration Sites Representing &gt;30% of the Total Integration Sites (2 Years)</measure>
    <time_frame>24 months</time_frame>
    <description>Vector Integration Site Analysis (VISA) allowed determination of the distribution of vector integration sites in each subject's genome, as well as the relative clonal abundance. VISA was to be considered abnormal for a subject if, in 2 or more instances during the course of follow-up, a single integration site was found to represent &gt;30% of the total integration sites detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Infection Rate Excluding the First Three Months After Treatment</measure>
    <time_frame>24 months</time_frame>
    <description>The infections of interest in this study were severe infections or opportunistic infectious episodes, defined as infections requiring hospitalization or prolonging hospitalization and/or documented infections by opportunistic pathogens. Infections that took place in the first 3 months of follow-up post treatment were excluded from calculations to avoid possible bias introduced in the data by the effects of conditioning.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>ADA-SCID</condition>
  <arm_group>
    <arm_group_label>Gene Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Infusion of autologous EFS-ADA LV CD34+ (OTL-101)</intervention_name>
    <description>autologous EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously</description>
    <arm_group_label>Gene Therapy</arm_group_label>
    <other_name>OTL-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Busulfan is used for non-myeloablative conditioning</description>
    <arm_group_label>Gene Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-ADA ERT</intervention_name>
    <description>PEG-ADA ERT is discontinued at Day +30 (-3/+15 days) after successful engraftment</description>
    <arm_group_label>Gene Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Children â¥ 1.0 months of age with a diagnosis of ADA-deficient SCID based on A. Decreased&#xD;
        ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured fetal&#xD;
        cells to levels consistent with ADA-deficient SCID as determined by reference laboratory or&#xD;
        confirmed ADA gene mutation(s) known to cause disease , AND&#xD;
&#xD;
        B. Evidence of severe combined immunodeficiency based on either:&#xD;
&#xD;
          1. Family history of first order relative with ADA deficiency and clinical and laboratory&#xD;
             evidence of severe immunologic deficiency, OR&#xD;
&#xD;
          2. Evidence of severe immunologic deficiency in subject prior to institution of immune&#xD;
             restorative therapy, based on&#xD;
&#xD;
               1. lymphopenia (absolute lymphocyte count &lt;400 cells/mcL) OR absence or low number&#xD;
                  of T cells (absolute CD3+ count &lt;300 cells/mcL) OR&#xD;
&#xD;
               2. severely decreased T lymphocyte blastogenic responses to phytohemagglutinin&#xD;
                  (either &lt;10% of lower limit of normal controls for the diagnostic laboratory,&#xD;
                  &lt;10% of the response of the normal control of the day, or stimulation index &lt;10)&#xD;
&#xD;
                    -  Ineligible for matched sibling allogeneic bone marrow transplantation:&#xD;
                       absence of a medically eligible HLA-identical sibling, with normal immune&#xD;
                       function, who may serve as an allogeneic bone marrow donor&#xD;
&#xD;
                    -  Signed written informed consent according to guidelines of the Institutional&#xD;
                       Review Board (IRB) (UCLA Office of Human Research Protection Program and&#xD;
                       National Human Genome Research Institute (NHGRI) IRB&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age â¤ 1.0 months Appropriate organ function as outlined below must be observed within&#xD;
             60 days of entering this trial.&#xD;
&#xD;
          2. Hematologic&#xD;
&#xD;
               1. Anemia (hemoglobin &lt; 10.5 g/dl at &lt; 2 years of age, or &lt; 11.5 g/dl at &gt; 2 years&#xD;
                  of age).&#xD;
&#xD;
               2. Neutropenia (absolute granulocyte count &lt;500/mm3.&#xD;
&#xD;
               3. Thrombocytopenia (platelet count &lt; 150,000/mm3, at any age).&#xD;
&#xD;
               4. International Normalised Ratio (INR) or Prothrombin Time (PT) &gt; 2 times the upper&#xD;
                  limits of normal or Partial Thromboplastin Time (PTT) &gt; 2.33 times the upper&#xD;
                  limit of normal (patients with a correctable deficiency controlled on medication&#xD;
                  will not be excluded).&#xD;
&#xD;
               5. Cytogenetic abnormalities on peripheral blood or bone marrow or amniotic fluid&#xD;
                  (if available).&#xD;
&#xD;
               6. Prior allogeneic Hematopoietic Stem Cell Transplant (HSCT) with cytoreductive&#xD;
                  conditioning&#xD;
&#xD;
          3. Infectious&#xD;
&#xD;
             a. Evidence of infection with HIV-1, hepatitis B, Hepatitis C, or parvovirus B 19 by&#xD;
             DNA Polymerase Chain Reaction (PCR) within 90 days prior to bone marrow harvest. If&#xD;
             other infection is present, it must be under control (e.g. stable or decreasing viral&#xD;
             load) at the time of screening&#xD;
&#xD;
          4. Pulmonary&#xD;
&#xD;
               1. Resting O2 saturation by pulse oximetry &lt; 95% on room air.&#xD;
&#xD;
               2. Chest x-ray indicating active or progressive pulmonary disease.&#xD;
&#xD;
          5. Cardiac&#xD;
&#xD;
               1. Abnormal electrocardiogram (EKG) indicating cardiac pathology.&#xD;
&#xD;
               2. Uncorrected congenital cardiac malformation with clinical symptomatology.&#xD;
&#xD;
               3. Active cardiac disease, including clinical evidence of congestive heart failure,&#xD;
                  cyanosis, hypotension.&#xD;
&#xD;
               4. Poor cardiac function as evidenced by LV ejection fraction &lt; 40% on&#xD;
                  echocardiogram.&#xD;
&#xD;
          6. Neurologic&#xD;
&#xD;
               1. Significant neurologic abnormality by examination.&#xD;
&#xD;
               2. Uncontrolled seizure disorder.&#xD;
&#xD;
          7. Renal&#xD;
&#xD;
               1. Renal insufficiency: serum creatinine &gt;= 1.2 mg/dl, or &gt;= 3+ proteinuria.&#xD;
&#xD;
               2. Abnormal serum sodium, potassium, calcium, magnesium, phosphate at grade III or&#xD;
                  IV by Division of AIDS Toxicity Scale.&#xD;
&#xD;
          8. Hepatic/GI:&#xD;
&#xD;
               1. Serum transaminases &gt; 5 times the upper limit of normal (ULN).&#xD;
&#xD;
               2. Serum bilirubin &gt; 2 times ULN.&#xD;
&#xD;
               3. Serum glucose &gt; 1.5 times ULN.&#xD;
&#xD;
               4. Intractable severe diarrhea.&#xD;
&#xD;
          9. Oncologic&#xD;
&#xD;
               1. Evidence of active malignant disease other than dermatofibrosarcoma protuberans&#xD;
                  (DFSP)&#xD;
&#xD;
               2. Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years&#xD;
                  following the infusion of genetically corrected cells&#xD;
&#xD;
               3. Evidence of DFSP expected to be life limiting within the 5 years following the&#xD;
                  infusion of genetically corrected cells&#xD;
&#xD;
         10. Known sensitivity to Busulfan&#xD;
&#xD;
         11. General&#xD;
&#xD;
               1. Expected survival &lt; 6 months.&#xD;
&#xD;
               2. Pregnant.&#xD;
&#xD;
               3. Major congenital anomaly.&#xD;
&#xD;
               4. Ineligible for autologous HSCT by the criteria at the clinical site.&#xD;
&#xD;
               5. Other conditions which in the opinion of the principal investigator and/or&#xD;
                  co-investigators, contra-indicate the bone marrow harvest, the administration of&#xD;
                  busulfan, infusion of transduced cells or indicate the patient or patient's&#xD;
                  parents/primary caregivers inability to follow protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald B Kohn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark O. Hatfield Clinical Research Center, NIH</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11.</citation>
    <PMID>22968453</PMID>
  </reference>
  <reference>
    <citation>Carbonaro DA, Zhang L, Jin X, Montiel-Equihua C, Geiger S, Carmo M, Cooper A, Fairbanks L, Kaufman ML, Sebire NJ, Hollis RP, Blundell MP, Senadheera S, Fu PY, Sahaghian A, Chan RY, Wang X, Cornetta K, Thrasher AJ, Kohn DB, Gaspar HB. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. 2014 Mar;22(3):607-622. doi: 10.1038/mt.2013.265. Epub 2013 Nov 20.</citation>
    <PMID>24256635</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <results_first_submitted>August 23, 2021</results_first_submitted>
  <results_first_submitted_qc>August 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <disposition_first_submitted>August 27, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 27, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 4, 2019</disposition_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>hematopoietic stem cell</keyword>
  <keyword>ADA-SCID</keyword>
  <keyword>lentiviral vector</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT01852071/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT01852071/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gene Therapy</title>
          <description>Infusion of autologous CD34+ cells genetically modified by the EF1Î±S-ADA (EFS-ADA) lentiviral vector (LV)&#xD;
Busulfan: Busulfan is used for non-myeloablative conditioning&#xD;
Polyethylene glycol-modified adenosine deaminase (PEG-ADA): PEG-ADA enzyme replacement therapy (ERT) is discontinued at Day 30 +/- 3 days from date of infusion of OTL-101.</description>
        </group>
        <group group_id="P2">
          <title>Historical Control Group</title>
          <description>Historical data from patients with Severe Combined Immunodeficiency Due to ADA Deficiency (ADA-SCID) who were treated with Hematopoietic Stem Cell Transplantation (HSCT): Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from Great Ormond Street Hospital (GOSH) and Duke University Children's Hospital were collected as comparator group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gene Therapy</title>
          <description>Infusion of autologous CD34+ cells genetically modified by the EF1Î±S-ADA (EFS-ADA) lentiviral vector (LV)&#xD;
Busulfan: Busulfan is used for non-myeloablative conditioning&#xD;
Polyethylene glycol-modified adenosine deaminase (PEG-ADA): PEG-ADA enzyme replacement therapy (ERT) is discontinued at Day 30 +/- 3 days from date of infusion of OTL-101.</description>
        </group>
        <group group_id="B2">
          <title>Historical Control Group</title>
          <description>Historical data from patients with Severe Combined Immunodeficiency Due to ADA Deficiency (ADA-SCID) who were treated with Hematopoietic Stem Cell Transplantation (HSCT): Historical data from a database of ADA-SCID patients treated with allogeneic HSCT from Great Ormond Street Hospital (GOSH) and Duke University Children's Hospital were collected as comparator group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex, n</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year)</title>
        <description>Overall survival is defined as the percentage of subjects alive at 12 months post- treatment with OTL-101 or HSCT</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at University of California, Los Angeles/National Institutes of Health (UCLA/NIH)</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible human leukocyte antigen (HLA)-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an Matched Related Donor (MRD) treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year)</title>
          <description>Overall survival is defined as the percentage of subjects alive at 12 months post- treatment with OTL-101 or HSCT</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.16" upper_limit="100"/>
                    <measurement group_id="O2" value="85.71" lower_limit="57.19" upper_limit="98.22"/>
                    <measurement group_id="O3" value="100" lower_limit="73.54" upper_limit="100"/>
                    <measurement group_id="O4" value="92.31" lower_limit="74.87" upper_limit="99.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients alive at 1-year post-treatment in the historical control groups (without MRD) were compared to the percentage of study patients alive at 1-year post-treatment with OTL-101. Results are reported as percentage difference in OS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>14.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.40</ci_lower_limit>
            <ci_upper_limit>42.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients alive at 1-year post-treatment in the historical control groups (with MRD) were compared to the percentage of study patients alive at 1-year post-treatment with OTL-101. Results are reported as percentage difference in OS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients alive at 1-year post-treatment in the historical control groups (all control patients) were compared to the percentage of study patients alive at 1-year post-treatment with OTL-101. Results are reported as percentage difference in OS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>7.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.08</ci_lower_limit>
            <ci_upper_limit>25.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival (EvFS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year)</title>
        <description>Event-free survival is defined as the percentage of subjects alive with no &quot;event&quot;, an &quot;event&quot; being the resumption of PEG-ADA ERT or the need for a rescue allogeneic Hematopoietic Stem Cell Transplant (HSCT), or death.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an MRD treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EvFS) of Subjects Treated With Investigational Medicinal Product (IMP) (1 Year)</title>
          <description>Event-free survival is defined as the percentage of subjects alive with no &quot;event&quot;, an &quot;event&quot; being the resumption of PEG-ADA ERT or the need for a rescue allogeneic Hematopoietic Stem Cell Transplant (HSCT), or death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.16" upper_limit="100"/>
                    <measurement group_id="O2" value="64.29" lower_limit="35.14" upper_limit="87.24"/>
                    <measurement group_id="O3" value="100" lower_limit="73.54" upper_limit="100"/>
                    <measurement group_id="O4" value="80.77" lower_limit="60.65" upper_limit="93.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with EvFS at 1-year post-treatment in the historical control groups (without MRD) were compared to the percentage of study patients with EvFS at 1-year post-treatment with OTL-101. Results are reported as percentage difference in EvFS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>35.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.21</ci_lower_limit>
            <ci_upper_limit>64.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with EvFS at 1-year post-treatment in the historical control groups (with MRD) were compared to the percentage of study patients with EvFS at 1-year post-treatment with OTL-101. Results are reported as percentage difference in EvFS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with EvFS at 1-year post-treatment in the historical control groups (all control patients) were compared to the percentage of study patients with EvFS at 1-year post-treatment with OTL-101. Results are reported as percentage difference in EvFS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>19.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>39.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years)</title>
        <description>OS is defined as the percentage of subjects alive at 24 months post- treatment with OTL-101 or HSCT</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an MRD treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>OS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years)</title>
          <description>OS is defined as the percentage of subjects alive at 24 months post- treatment with OTL-101 or HSCT</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.16" upper_limit="100"/>
                    <measurement group_id="O2" value="85.71" lower_limit="57.19" upper_limit="98.22"/>
                    <measurement group_id="O3" value="90.91" lower_limit="58.72" upper_limit="99.77"/>
                    <measurement group_id="O4" value="88.00" lower_limit="68.78" upper_limit="97.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients alive at 2-years post-treatment in the historical control groups (without MRD) were compared to the percentage of study patients alive at 2-years post-treatment with OTL-101. Results are reported as percentage difference in OS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>14.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.40</ci_lower_limit>
            <ci_upper_limit>42.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients alive at 2-years post-treatment in the historical control groups (with MRD) were compared to the percentage of study patients alive at 2-years post-treatment with OTL-101. Results are reported as percentage difference in OS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>9.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.55</ci_lower_limit>
            <ci_upper_limit>41.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients alive at 2-years post-treatment in the historical control groups (all control patients) were compared to the percentage of study patients alive at 2-years post-treatment with OTL-101. Results are reported as percentage difference in OS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>12.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.62</ci_lower_limit>
            <ci_upper_limit>31.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EvFS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years)</title>
        <description>Event-free survival is defined as the percentage of subjects alive with no &quot;event&quot;, an &quot;event&quot; being the resumption of PEG-ADA ERT or the need for a rescue allogenic Hematopoietic Stem Cell Transplant (HSCT), or death.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an MRD treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>EvFS of Subjects Treated With Investigational Medicinal Product (IMP) (2 Years)</title>
          <description>Event-free survival is defined as the percentage of subjects alive with no &quot;event&quot;, an &quot;event&quot; being the resumption of PEG-ADA ERT or the need for a rescue allogenic Hematopoietic Stem Cell Transplant (HSCT), or death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="83.16" upper_limit="100"/>
                    <measurement group_id="O2" value="50.00" lower_limit="23.04" upper_limit="76.96"/>
                    <measurement group_id="O3" value="63.64" lower_limit="30.79" upper_limit="89.07"/>
                    <measurement group_id="O4" value="56.00" lower_limit="34.93" upper_limit="75.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with EvFS at 2-years post-treatment in the historical control groups (without MRD) were compared to the percentage of study patients with EvFS at 2-years post-treatment with OTL-101. Results are reported as percentage difference in EvFS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>50.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.71</ci_lower_limit>
            <ci_upper_limit>76.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with EvFS at 2-years post-treatment in the historical control groups (with MRD) were compared to the percentage of study patients with EvFS at 2-years post-treatment with OTL-101. Results are reported as percentage difference in EvFS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>36.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.80</ci_lower_limit>
            <ci_upper_limit>69.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of patients with EvFS at 2-years post-treatment in the historical control groups (all control patients) were compared to the percentage of study patients with EvFS at 2-years post-treatment with OTL-101. Results are reported as percentage difference in EvFS of historical control group from OTL-101 on-study subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Difference in percentages</param_type>
            <param_value>44.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.78</ci_lower_limit>
            <ci_upper_limit>65.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vector Copy Number (VCN) in Peripheral Blood (PB) Granulocytes.</title>
        <description>Vector copy number in the PB granulocyte fraction that was T cell depleted, is a surrogate for amount of engrafted genetically modified Hematopoietic stem cell (HSC) that are producing granulocytes every 3-5 days. VCN analysis was performed by Droplet Digital PCR (ddPCR) on DNA extracted from peripheral blood granulocytes.</description>
        <time_frame>24 months</time_frame>
        <population>Historical control groups/arms are not included in the analysis population for this outcome measure as these subjects did not receive gene therapy, and so measurement of VCN levels is not relevant</population>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
        </group_list>
        <measure>
          <title>Vector Copy Number (VCN) in Peripheral Blood (PB) Granulocytes.</title>
          <description>Vector copy number in the PB granulocyte fraction that was T cell depleted, is a surrogate for amount of engrafted genetically modified Hematopoietic stem cell (HSC) that are producing granulocytes every 3-5 days. VCN analysis was performed by Droplet Digital PCR (ddPCR) on DNA extracted from peripheral blood granulocytes.</description>
          <population>Historical control groups/arms are not included in the analysis population for this outcome measure as these subjects did not receive gene therapy, and so measurement of VCN levels is not relevant</population>
          <units>copies/cell</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.093" lower_limit="0.04" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VCN in Peripheral Blood Mononuclear Cells (PBMCs)</title>
        <description>PBMC VCN is a measure of the accumulation of peripheral blood leukocytes arising from engrafted, genetically modified HSC. VCN analysis was performed by ddPCR on DNA extracted from PBMC.</description>
        <time_frame>24 months</time_frame>
        <population>Historical control groups/arms are not included in the analysis population for this outcome measure as these subjects did not receive gene therapy, and so measurement of VCN levels is not relevant</population>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
        </group_list>
        <measure>
          <title>VCN in Peripheral Blood Mononuclear Cells (PBMCs)</title>
          <description>PBMC VCN is a measure of the accumulation of peripheral blood leukocytes arising from engrafted, genetically modified HSC. VCN analysis was performed by ddPCR on DNA extracted from PBMC.</description>
          <population>Historical control groups/arms are not included in the analysis population for this outcome measure as these subjects did not receive gene therapy, and so measurement of VCN levels is not relevant</population>
          <units>copies/cell</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" lower_limit="0.13" upper_limit="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADA Activity in Erythrocytes</title>
        <description>ADA enzyme activity measured to assess the amount of functional gene product produced from the normal ADA transgene delivered by EFS-ADA LV; persistence of ADA enzyme activity over time demonstrates successful engraftment and differentiation of genetically modified HSC.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an MRD treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>ADA Activity in Erythrocytes</title>
          <description>ADA enzyme activity measured to assess the amount of functional gene product produced from the normal ADA transgene delivered by EFS-ADA LV; persistence of ADA enzyme activity over time demonstrates successful engraftment and differentiation of genetically modified HSC.</description>
          <units>nmol/h/mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.50" lower_limit="34.1" upper_limit="268.9"/>
                    <measurement group_id="O2" value="48.500" lower_limit="0.00" upper_limit="123.00"/>
                    <measurement group_id="O3" value="1.000" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="2.000" lower_limit="0.00" upper_limit="123.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in Deoxyadenosine Nucleotide (dAXP) in Erythrocytes</title>
        <description>Decreased dAXP levels coincide with increased ADA enzyme activity, detoxification was used to demonstrate functional ADA enzyme production from the introduced ADA transgene. The threshold for detoxification was &lt;100 Î¼mol/L.</description>
        <time_frame>24 months</time_frame>
        <population>HSCT Controls With MRD arm is not included in the analysis population for this outcome measure as dAXP data was not reported between 17-30 months post-HSCT for any patients in this arm.</population>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Deoxyadenosine Nucleotide (dAXP) in Erythrocytes</title>
          <description>Decreased dAXP levels coincide with increased ADA enzyme activity, detoxification was used to demonstrate functional ADA enzyme production from the introduced ADA transgene. The threshold for detoxification was &lt;100 Î¼mol/L.</description>
          <population>HSCT Controls With MRD arm is not included in the analysis population for this outcome measure as dAXP data was not reported between 17-30 months post-HSCT for any patients in this arm.</population>
          <units>umol/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0330" lower_limit="0.007" upper_limit="0.101"/>
                    <measurement group_id="O2" value="0.0360" lower_limit="0.004" upper_limit="0.256"/>
                    <measurement group_id="O3" value="0.0360" lower_limit="0.004" upper_limit="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD3+ T Cell Counts (2 Years)</title>
        <description>Immune reconstitution was assessed by change in CD3+ T Cell counts over time.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an MRD treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD3+ T Cell Counts (2 Years)</title>
          <description>Immune reconstitution was assessed by change in CD3+ T Cell counts over time.</description>
          <units>cells/Î¼L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="569.0" lower_limit="-426" upper_limit="2211"/>
                    <measurement group_id="O2" value="340.0" lower_limit="-23" upper_limit="1243"/>
                    <measurement group_id="O3" value="538.0" lower_limit="538" upper_limit="538"/>
                    <measurement group_id="O4" value="395.5" lower_limit="-23" upper_limit="1243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Single Integration Sites Representing &gt;30% of the Total Integration Sites (2 Years)</title>
        <description>Vector Integration Site Analysis (VISA) allowed determination of the distribution of vector integration sites in each subject's genome, as well as the relative clonal abundance. VISA was to be considered abnormal for a subject if, in 2 or more instances during the course of follow-up, a single integration site was found to represent &gt;30% of the total integration sites detected.</description>
        <time_frame>24 months</time_frame>
        <population>Historical control groups/arms are not included in the analysis population for this outcome measure as these subjects did not receive gene therapy, and so measurement of VISA is not relevant</population>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary safety population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Single Integration Sites Representing &gt;30% of the Total Integration Sites (2 Years)</title>
          <description>Vector Integration Site Analysis (VISA) allowed determination of the distribution of vector integration sites in each subject's genome, as well as the relative clonal abundance. VISA was to be considered abnormal for a subject if, in 2 or more instances during the course of follow-up, a single integration site was found to represent &gt;30% of the total integration sites detected.</description>
          <population>Historical control groups/arms are not included in the analysis population for this outcome measure as these subjects did not receive gene therapy, and so measurement of VISA is not relevant</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Infection Rate Excluding the First Three Months After Treatment</title>
        <description>The infections of interest in this study were severe infections or opportunistic infectious episodes, defined as infections requiring hospitalization or prolonging hospitalization and/or documented infections by opportunistic pathogens. Infections that took place in the first 3 months of follow-up post treatment were excluded from calculations to avoid possible bias introduced in the data by the effects of conditioning.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OTL-101 Gene Therapy</title>
            <description>The primary efficacy population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
          </group>
          <group group_id="O2">
            <title>HSCT Controls Without MRD</title>
            <description>The primary comparator population from the HSCT historical control group consists of ADA-SCID patients without a medically eligible HLA-identical sibling or family donor and treated with HSCT at either GOSH or Duke University between 2000 and 2016.</description>
          </group>
          <group group_id="O3">
            <title>HSCT Controls With MRD</title>
            <description>ADA-SCID patients with an MRD treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
          <group group_id="O4">
            <title>All HSCT Control Group</title>
            <description>The complete HSCT historical control group, which consists of ADA-SCID patients with any type of donor treated with HSCT at either GOSH or Duke University from 2000 to 2016</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Infection Rate Excluding the First Three Months After Treatment</title>
          <description>The infections of interest in this study were severe infections or opportunistic infectious episodes, defined as infections requiring hospitalization or prolonging hospitalization and/or documented infections by opportunistic pathogens. Infections that took place in the first 3 months of follow-up post treatment were excluded from calculations to avoid possible bias introduced in the data by the effects of conditioning.</description>
          <units>Infection rate per person per year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20"/>
                    <measurement group_id="O2" value="0.56"/>
                    <measurement group_id="O3" value="0.15"/>
                    <measurement group_id="O4" value="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time of participant consent, approximately 1-month pre-treatment, up until 2-years post-treatment with OTL-101</time_frame>
      <desc>Adverse events were reported for subjects treated with OTL-101.&#xD;
Adverse event reporting is not applicable for the historical control arms (without MRD, with MRD, and all control patients) as this data was not collected due to the historical nature of the population.</desc>
      <group_list>
        <group group_id="E1">
          <title>OTL-101 Gene Therapy</title>
          <description>The safety population consists of all subjects treated with OTL-101 at UCLA/NIH</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ear injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Body temperature decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Influenza B virus test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Orchard Medical Information</name_or_title>
      <organization>Orchard Therapeutics (Europe) Ltd</organization>
      <phone>+44 (0) 203 808 8286</phone>
      <email>medinfo@orchard-tx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

